走进诺和诺德 更多 >>
诺和诺德是一家致力于人类健康、以先进的生物技术造福患者、医生和社会的世界领先生物制药公司。
诺和诺德公司的历史最早可追溯至1923年，80多年来一直是世界糖尿病研究和药物开发领域的主导。诺和诺德总部位于丹麦首都哥本哈根，现在全球79个国家设有分支机构，6个国家设有生产厂，截至08年底，员工超过 27，000名，销售遍及180个国家。
诺和诺德凭借自身的研发实力成为世界糖尿病治疗领域先导，在行业内拥有最为广泛的糖尿病治疗产品，其中包括最先进的胰岛素给药系统产品。
杨文英教授：肥胖及2型糖尿病流行的东西方差异
East and West: The impact of global obesity and the type 2 diabetes epidemic
Dr. Wenying Yang
Director of Endocrinology Department China-Japan Friendship Hospital
ex-Chairman, Chinese Medical Association Diabetes Society Beijing, China
杨文英教授介绍了2型糖尿病流行现状及东西方差异。她指出，糖尿病迅猛流行势不可挡，尤其在亚洲，随着城市化进程带来的生活方式改变，糖尿病患病率迅速增加。而且，与西方人群相比，亚洲2型糖尿病患者有其自身特点：①发病更早，30~40岁人群发病率较高，且大多数患者为45~64岁；②β细胞功能受损更早且更严重；③总体肥胖率较低但腹型肥胖不容忽视。根据这些特点，对亚洲2型糖尿病患者的治疗也应强调个体化，针对其发病早，以β细胞功能受损为主的病生理特点，选择合理的治疗方式。
Global projections for the diabetes epidemic are estimated to increase from 285 million to 438 million people worldwide within the next 20 years; a remarkable 65% increase. In addition, a rapidly growing prevalence of type 2 diabetes is evident within the different continent. Professor Yang will address several factors that are associated with the impact of global obesity and the type 2 diabetes epidemic in different populations. First, epidemiology and environmental change, the impact of diet and reduced physical activity because of changing occupations and urbanisation will be explored. Secondly, the effects of insulin secretory defects and the ethnic differences between insulin resistance and genetic susceptibility to type 2 diabetes will be considered for the need of primary prevention.
杨文英教授：肥胖与2型糖尿病流行的东西方差异
查看分页PPT： http://meeting.dxy.cn/2009asia_summit/article/i9914.html
编辑: xiaoyan
以下网友留言只代表网友个人观点，不代表网站观点
